Phase II Study in advanced breast cancer:

Progression-free survival in breast cancer extended by 74 percent

A new study is yielding positive results for the treatment of breast cancer with Nexavar® in combination with chemotherapy.

Zoom image

A new study is yielding positive results for the treatment of breast cancer with Nexavar® in combination with chemotherapy.

Nexavar® may also have the potential to improve treatment of advanced breast cancer. In a clinical Phase II study, the anti-cancer drug from Bayer in combination with the oral chemotherapeutic agent capecitabine was more effective than treatment with capecitabine alone. Specifically, this combination extended progression-free survival by 74 percent. The data were presented at a medical congress in Berlin at the end of September.

“Building on these positive trial data, we are committed to the development of Nexavar® to treat breast cancer in a variety of settings through a robust clinical program,” said Dimitris Voliotis, responsible for the global clinical development of Nexavar® at Bayer HealthCare.

Nexavar® is currently approved in many countries for the treatment of renal cell carcinoma and hepatocellular carcinoma. Its possible use in a wide range of cancers is also currently being evaluated in various clinical studies.